Monday, May 7, 2007

Dendreon (DNDN)

An analyst at Stanford lowered odds of approval for Dendreon's (DNDN) Provenge down to 40% from 80% following review of briefing documents. FDA to decide on the fate of Provenge by May 15th.

I remain long, but well hedged.
Posted by Unknown at 3:58 PM

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)